News Zai Lab Limited

Stocks

ZLAB

US98887Q1040

Pharmaceuticals

Market Closed - Nasdaq 23:00:00 14/08/2026 +03			5-day change	1st Jan Change
25.90 ^USD	-0.50%		+11.06%	+46.83%

08-13	Asian Equities Traded in the US as American Depositary Receipts Marginally Higher in Thursday Trading	MT
08-11	Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading	MT

All News

Mentions Relevance

08-06	Zai Lab Limited, Q2 2026 Earnings Call, Aug 06, 2026
08-06	Zai Lab Shares Rise After Q2 Beat	MT
08-06	Zai Lab Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Revenue $106.3M, vs. FactSet Est of $103.9M	MT
08-06	Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Loss of $0.46 per ADS, vs. FactSet Est of $-0.68	MT
08-06	Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates	BU
08-03	Zai Lab Receives FDA Orphan Drug Designation for Zocilurtatug Pelitecan in Neuroendocrine Carcinomas	MT
08-03	U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)	BU
07-22	Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026	BU
06-29	Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing	MT
06-17	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan in Pulmonary Neuroendocrine Carcinomas	AQ
06-16	Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug	MT
06-16	Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas	BU
06-09	Zai Lab Says China Approves Tivdak for Cervical Cancer Treatment	MT
06-09	Zai Lab Receives China NMPA Approval For TIVDAK For Treatment Of Recurrent Or Metastatic Cervical Cancer	CI
06-09	Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer	BU
05-22	Zai Lab President, COO Josh Smiley to Depart	MT
05-22	Zai Lab Ousts COO Josh Smiley	MT
05-22	Zai Lab Announces Changes to Senior Leadership Team	BU
05-22	Zai Lab Limited Announces Departure of Josh Smiley as President and COO, Effective May 22, 2026	CI
05-19	Zai Lab Insider Sold Shares Worth $1,986,875, According to a Recent SEC Filing	MT
05-15	Zai Lab Insider Sold Shares Worth $2,003,044, According to a Recent SEC Filing	MT
05-11	Zai Lab Limited Receives FDA Fast Track Designation for Zocilurtatug Pelitecan for Treatment of Extrapulmonary Neuroendocrine Carcinomas	CI
05-11	Zai Lab Receives FDA's Fast Track Designation for Zoci in Extrapulmonary Neuroendocrine Carcinomas	MT
05-11	Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)	BU